Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte- predominant and classic Hodgkin lymphoma

Arcangelo Liso, Daniela Capello, Teresa Marafioti, Enrico Tiacci, Michaela Cerri, Verena Distler, Marco Paulli, Antonino Carbone, Georges Delsol, Elias Campo, Stefano Pileri, Laura Pasqualucci, Gianluca Gaidano, Brunangelo Falini

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Aberrant somatic hypermutation (SHM) has been identified as a mechanism for genomewide instability in diffuse large B-cell lymphoma (DLBCL). To assess whether aberrant SHM plays a role in the molecular pathogenesis of Hodgkin lymphoma (HL), we investigated microdissected neoplastic cells of nodular lymphocyte-predominant HL (NLPHL; n = 10) and classic HL (cHL; n = 9) for the presence of mutations in the 5′ sequences of 4 previously identified aberrant SHM targets (PIM1, PAX5, RhoH/TTF, c-MYC). Mutations in one or more genes were detected in 80% of NLPHLs and 55% of cHLs, with 50% and 30% of patients carrying mutations in 2 or more genes, respectively. The most frequently involved protooncogene was PAX5, mutated in 7 of 9 patients with NLPHL and 2 of 9 patients with cHL. In total, 34 mutations were detected in NLPHL (frequency, 1.04/1000 bp) and 35 were detected in patients with cHL (frequency, 1.92/1000 bp). Mutations were of somatic origin because they were absent in control T cells and shared most of the features of the immunoglobulin variable (IGV) gene-associated SHM mechanism - ie, single nucleotide substitutions (n = 63) with rare deletions/insertions (n = 6) and a predominance of transitions over transversions with preferential targeting motifs. Our finding that NLPHL and cHL are targeted by aberrant SHM, as is DLBCL, suggests that these lymphomas may share common molecular pathogenetic events.

Original languageEnglish
Pages (from-to)1013-1020
Number of pages8
JournalBlood
Volume108
Issue number3
DOIs
Publication statusPublished - Aug 1 2006

Fingerprint

Lymphocytes
Hodgkin Disease
Tumors
Genes
Cells
Mutation
Lymphoma, Large B-Cell, Diffuse
Neoplasms
T-cells
Immunoglobulins
Substitution reactions
Nucleotides
Immunoglobulin Genes
Lymphoma
T-Lymphocytes

ASJC Scopus subject areas

  • Hematology

Cite this

Liso, A., Capello, D., Marafioti, T., Tiacci, E., Cerri, M., Distler, V., ... Falini, B. (2006). Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte- predominant and classic Hodgkin lymphoma. Blood, 108(3), 1013-1020. https://doi.org/10.1182/blood-2005-10-3949

Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte- predominant and classic Hodgkin lymphoma. / Liso, Arcangelo; Capello, Daniela; Marafioti, Teresa; Tiacci, Enrico; Cerri, Michaela; Distler, Verena; Paulli, Marco; Carbone, Antonino; Delsol, Georges; Campo, Elias; Pileri, Stefano; Pasqualucci, Laura; Gaidano, Gianluca; Falini, Brunangelo.

In: Blood, Vol. 108, No. 3, 01.08.2006, p. 1013-1020.

Research output: Contribution to journalArticle

Liso, A, Capello, D, Marafioti, T, Tiacci, E, Cerri, M, Distler, V, Paulli, M, Carbone, A, Delsol, G, Campo, E, Pileri, S, Pasqualucci, L, Gaidano, G & Falini, B 2006, 'Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte- predominant and classic Hodgkin lymphoma', Blood, vol. 108, no. 3, pp. 1013-1020. https://doi.org/10.1182/blood-2005-10-3949
Liso, Arcangelo ; Capello, Daniela ; Marafioti, Teresa ; Tiacci, Enrico ; Cerri, Michaela ; Distler, Verena ; Paulli, Marco ; Carbone, Antonino ; Delsol, Georges ; Campo, Elias ; Pileri, Stefano ; Pasqualucci, Laura ; Gaidano, Gianluca ; Falini, Brunangelo. / Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte- predominant and classic Hodgkin lymphoma. In: Blood. 2006 ; Vol. 108, No. 3. pp. 1013-1020.
@article{0345d03ca4e34f2babdd051857be491e,
title = "Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte- predominant and classic Hodgkin lymphoma",
abstract = "Aberrant somatic hypermutation (SHM) has been identified as a mechanism for genomewide instability in diffuse large B-cell lymphoma (DLBCL). To assess whether aberrant SHM plays a role in the molecular pathogenesis of Hodgkin lymphoma (HL), we investigated microdissected neoplastic cells of nodular lymphocyte-predominant HL (NLPHL; n = 10) and classic HL (cHL; n = 9) for the presence of mutations in the 5′ sequences of 4 previously identified aberrant SHM targets (PIM1, PAX5, RhoH/TTF, c-MYC). Mutations in one or more genes were detected in 80{\%} of NLPHLs and 55{\%} of cHLs, with 50{\%} and 30{\%} of patients carrying mutations in 2 or more genes, respectively. The most frequently involved protooncogene was PAX5, mutated in 7 of 9 patients with NLPHL and 2 of 9 patients with cHL. In total, 34 mutations were detected in NLPHL (frequency, 1.04/1000 bp) and 35 were detected in patients with cHL (frequency, 1.92/1000 bp). Mutations were of somatic origin because they were absent in control T cells and shared most of the features of the immunoglobulin variable (IGV) gene-associated SHM mechanism - ie, single nucleotide substitutions (n = 63) with rare deletions/insertions (n = 6) and a predominance of transitions over transversions with preferential targeting motifs. Our finding that NLPHL and cHL are targeted by aberrant SHM, as is DLBCL, suggests that these lymphomas may share common molecular pathogenetic events.",
author = "Arcangelo Liso and Daniela Capello and Teresa Marafioti and Enrico Tiacci and Michaela Cerri and Verena Distler and Marco Paulli and Antonino Carbone and Georges Delsol and Elias Campo and Stefano Pileri and Laura Pasqualucci and Gianluca Gaidano and Brunangelo Falini",
year = "2006",
month = "8",
day = "1",
doi = "10.1182/blood-2005-10-3949",
language = "English",
volume = "108",
pages = "1013--1020",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte- predominant and classic Hodgkin lymphoma

AU - Liso, Arcangelo

AU - Capello, Daniela

AU - Marafioti, Teresa

AU - Tiacci, Enrico

AU - Cerri, Michaela

AU - Distler, Verena

AU - Paulli, Marco

AU - Carbone, Antonino

AU - Delsol, Georges

AU - Campo, Elias

AU - Pileri, Stefano

AU - Pasqualucci, Laura

AU - Gaidano, Gianluca

AU - Falini, Brunangelo

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Aberrant somatic hypermutation (SHM) has been identified as a mechanism for genomewide instability in diffuse large B-cell lymphoma (DLBCL). To assess whether aberrant SHM plays a role in the molecular pathogenesis of Hodgkin lymphoma (HL), we investigated microdissected neoplastic cells of nodular lymphocyte-predominant HL (NLPHL; n = 10) and classic HL (cHL; n = 9) for the presence of mutations in the 5′ sequences of 4 previously identified aberrant SHM targets (PIM1, PAX5, RhoH/TTF, c-MYC). Mutations in one or more genes were detected in 80% of NLPHLs and 55% of cHLs, with 50% and 30% of patients carrying mutations in 2 or more genes, respectively. The most frequently involved protooncogene was PAX5, mutated in 7 of 9 patients with NLPHL and 2 of 9 patients with cHL. In total, 34 mutations were detected in NLPHL (frequency, 1.04/1000 bp) and 35 were detected in patients with cHL (frequency, 1.92/1000 bp). Mutations were of somatic origin because they were absent in control T cells and shared most of the features of the immunoglobulin variable (IGV) gene-associated SHM mechanism - ie, single nucleotide substitutions (n = 63) with rare deletions/insertions (n = 6) and a predominance of transitions over transversions with preferential targeting motifs. Our finding that NLPHL and cHL are targeted by aberrant SHM, as is DLBCL, suggests that these lymphomas may share common molecular pathogenetic events.

AB - Aberrant somatic hypermutation (SHM) has been identified as a mechanism for genomewide instability in diffuse large B-cell lymphoma (DLBCL). To assess whether aberrant SHM plays a role in the molecular pathogenesis of Hodgkin lymphoma (HL), we investigated microdissected neoplastic cells of nodular lymphocyte-predominant HL (NLPHL; n = 10) and classic HL (cHL; n = 9) for the presence of mutations in the 5′ sequences of 4 previously identified aberrant SHM targets (PIM1, PAX5, RhoH/TTF, c-MYC). Mutations in one or more genes were detected in 80% of NLPHLs and 55% of cHLs, with 50% and 30% of patients carrying mutations in 2 or more genes, respectively. The most frequently involved protooncogene was PAX5, mutated in 7 of 9 patients with NLPHL and 2 of 9 patients with cHL. In total, 34 mutations were detected in NLPHL (frequency, 1.04/1000 bp) and 35 were detected in patients with cHL (frequency, 1.92/1000 bp). Mutations were of somatic origin because they were absent in control T cells and shared most of the features of the immunoglobulin variable (IGV) gene-associated SHM mechanism - ie, single nucleotide substitutions (n = 63) with rare deletions/insertions (n = 6) and a predominance of transitions over transversions with preferential targeting motifs. Our finding that NLPHL and cHL are targeted by aberrant SHM, as is DLBCL, suggests that these lymphomas may share common molecular pathogenetic events.

UR - http://www.scopus.com/inward/record.url?scp=33746631684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746631684&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-10-3949

DO - 10.1182/blood-2005-10-3949

M3 - Article

VL - 108

SP - 1013

EP - 1020

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -